BMPRIA showed no association with five-year survival rate or with survival time of ovarian PARP assay Protein Tyrosine Kinase inhibitor cancer patients. BMP-2, BMPRIB, and BMPRII may play a part in the occurrence and development of ovarian cancer, and the variation or loss of expression of BMP-2, BMPRIB, and BMPRII may be an indicator of poor prognosis for ovarian cancer patients. Further studies conducted with larger sample sizes are needed to confirm this association. Our study suggests that BMP-2 and its receptors BMPRIB and BMPRII are likely to be involved in the development of ovarian cancer, and attenuation or loss of expression may result in or indicate poor prognosis for ovarian cancer patients. However, the

specific pathway and mechanisms driving this effect need further study, if novel treatments for ovarian cancer are to be achieved through better understanding of its pathogenesis. Conclusions BMP-2, BMPRIB, and BMPRII exhibited a low expression in EOC tissue. The variation or loss of expression of these markers may indicate poor prognosis for ovarian cancer patients. Acknowledgements This study was supported by China National

Nature Science Fund (No.30100104) to Dr. Lin Ma. References 1. Ni X, Gu S, Dai J, Cheng H, Guo L, Li L, Ji C, Xie Y, Ying K, Mao Y: Isolation and characterization of a novel human NM23-H1B gene, a different transcript of NM23-H1. J Hum Genet 2003,48(2):96–100.PubMedCrossRef 2. Wozney JM: The bone morphogenetic protein family: multifunctional cellular regulators in the embryo and adult. Eur J Oral Sci 1998,106(Suppl 1):160–166.PubMed 3. Miyazono K, Kusanagi K, Inoue GSI-IX clinical trial H: Divergence

and convergence of TGF-beta/BMP signaling. J Cell Physiol 2001,187(3):265–276.PubMedCrossRef 4. Ghosh-Choudhury N, Ghosh-Choudhury G, Celeste A, Ghosh PM, Moyer M, Abboud SL, Kreisberg J: Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. Biochim Biophys Acta 2000,1497(2):186–196.PubMedCrossRef 5. Dumont N, Arteaga CL: A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells. Biochem Biophys Res Commun 2003,301(1):108–112.PubMedCrossRef 6. Ghosh-Choudhury N, Woodruff K, Qi W, Celeste A, Abboud SL, Ghosh Choudhury Urease G: Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. Biochem Biophys Res Commun 2000,272(3):705–711.PubMedCrossRef 7. Tada A, Nishihara T, Kato H: Bone morphogenetic protein 2 suppresses the transformed phenotype and restores actin microfilaments of human lung carcinoma A549 cells. Oncol Rep 1998,5(5):1137–1140.PubMed 8. Langenfeld EM, Bojnowski J, Perone J, Langenfeld J: Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg 2005,80(3):1028–1032.PubMedCrossRef 9.